Zyversa therapeutics announces published data showing inflammasome asc inhibitor ic 100 decreases microglial inflammasome activation and alpha-synuclein that contribute to neurodegeneration in parkinson's disease

Zyversa's ic 100 blocked microglial nlrp1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for parkinson's disease

ASC Ratings Summary

ASC Quant Ranking